Long-term Results of Tacrolimus Monotherapy in Cardiac Transplant Recipients

Journal of Heart and Lung Transplantation

Volumn 25, Issue 6, 2006, Pages 699-706

  Lubitz, Steven A ^a   Baran, David A ^b   Alwarshetty, Mamata M ^b   Pinney, Sean ^a   Kaplan, Sarah ^c   Chan, Ming ^a   Courtney, Mary C ^a   Lansman, Steven L ^c   Spielvogel, David ^c   Gass, Alan L ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOSPORIN; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ADULT; CORONARY ANGIOGRAPHY; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 33646779150     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.02.003     Document Type: Article

References (34)

1. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 23 suppl 5 (2004) S202
2. O'Neill J.O., Taylor D.O., and Starling R.C. Immunosuppression for cardiac transplantation-the past, present and future. Transplant Proc 36 suppl 2 (2004) 309S
3. Felkel T.O., Smith A.L., Reichenspurner H.C., et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J Heart Lung Transplant 21 (2002) 530
4. Olivari M.T., Jessen M.E., Baldwin B.J., et al. Triple-drug immunosuppression with steroid discontinuation by 6 months after heart transplantation. J Heart Lung Transplant 14 (1995) 127
5. Opelz G., Dohler B., and Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5 (2005) 720
6. Taylor D.O., Bristow M.R., O'Connell J.B., et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 15 (1996) 1039
7. Cantin B., Kwok B.W., Shiba N., et al. Post-operative conversion from cyclosporine to tacrolimus in heart transplantation. a single-center experience. J Heart Lung Transplant 22 (2003) 723
8. Pollock-Barziv S.M., Dipchand A.I., McCrindle B.W., Nalli N., and West L.J. Randomized clinical trial of tacrolimus- vs cyclosporine-based immunosuppression in pediatric heart transplantation. preliminary results at 15-month follow-up. J Heart Lung Transplant 24 (2005) 190
9. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 24 (2005) 119
10. Verleden G.M., Dupont L.J., Van Raemdonck D., and Vanhaecke J. Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J Heart Lung Transplant 22 (2003) 908
11. Villanueva J., Boukhamseen A., and Bhorade S.M. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. J Heart Lung Transplant 24 (2005) 421
12. White M., Haddad H., Leblanc M.H., et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia. the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant 24 (2005) 798
13. Baran D.A., Galin I., Sandler D., et al. Tacrolimus in cardiac transplantation. efficacy and safety of a novel dosing protocol. Transplantation 74 (2002) 1136
14. Baran D.A., Galin I.D., Sandler D., et al. A novel tacrolimus dosing strategy in cardiac transplantation. drug levels, renal function, and biopsy results. Transplant Proc 34 (2002) 1834
15. Baran D.A., Segura L., Kushwaha S., et al. Tacrolimus monotherapy in adult cardiac transplant recipients. intermediate-term results. J Heart Lung Transplant 20 (2001) 59
16. Baran D.A., Galin I.D., Sandler D., et al. Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. Transplant Proc 34 (2002) 1872
17. Baran D.A., Galin I.D., Zucker M.J., et al. Can initial tacrolimus trough levels be predicted from clinical variables?. Transplant Proc 36 (2004) 2816
18. Baran D.A., Galin I.D., Segura L., et al. Tacrolimus and cardiac transplantation. a comparison of monotherapy and steroid-dependent patients. Transplant Proc 34 (2002) 1845
19. Billingham M.E., Cary N.R., Hammond M.E., et al., Heart Rejection Study Group, The International Society for Heart Transplantation. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplant 9 (1990) 587
20. Taylor D.O., Edwards L.B., Boucek M.M., et al. The registry of the International Society for Heart and Lung Transplantation. twenty-first official adult heart transplant report-2004. J Heart Lung Transplant 23 (2004) 796
21. Patel J.K., and Kobashigawa J.A. Immunosuppression, diagnosis, and treatment of cardiac allograft rejection. Semin Thorac Cardiovasc Surg 16 (2004) 378
22. Hosenpud J.D. Immunosuppression in cardiac transplantation. N Engl J Med 352 (2005) 2749
23. Pinney S.P., and Mancini D. Cardiac allograft vasculopathy. advances in understanding its pathophysiology, prevention, and treatment. Curr Opin Cardiol 19 (2004) 170
24. Valantine H. Cardiac allograft vasculopathy after heart transplantation. risk factors and management. J Heart Lung Transplant 23 suppl 5 (2004) S187
25. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621
26. Schroeder J.S., Gao S.Z., Alderman E.L., et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 328 (1993) 164
27. Wenke K., Meiser B., Thiery J., et al. Simvastatin initiated early after heart transplantation. 8-year prospective experience. Circulation 107 (2003) 93
28. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. a four-year randomized trial. Circulation 96 (1997) 1398
29. Valantine H.A. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 4 (2004) 169
30. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931
31. Woolfson R.G., and Neild G.H. Cyclosporin nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant 12 (1997) 2054
32. Pinto F.J., Chenzbraun A., Botas J., et al. Feasibility of serial intracoronary ultrasound imaging for assessment of progression of intimal proliferation in cardiac transplant recipients. Circulation 90 (1994) 2348
33. St Goar F.G., Pinto F.J., Alderman E.L., et al. Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening. Circulation 85 (1992) 979
34. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients. outcomes after five years. JAMA 45 (2005) 1532